Maintenance bevacizumab after first-line treatment in HER2-negative metastatic breast cancer patients.
A. Fabi
No relevant relationships to disclose
M. Russillo
No relevant relationships to disclose
G. Metro
No relevant relationships to disclose
P. Papaldo
No relevant relationships to disclose
C. Nisticò
No relevant relationships to disclose
G. Ferretti
No relevant relationships to disclose
F. Cuppone
No relevant relationships to disclose
G. D'Auria
No relevant relationships to disclose
D. Giannarelli
No relevant relationships to disclose
F. Cognetti
No relevant relationships to disclose